EUVIMED · CrossrefJournal
Cancer Treatment Reviews
ISSN 0305-7372 · Elsevier BV
Latest articles
T-cell engagers in small-cell lung cancer: current evidence and future directions – a position statement from the ETOP IBCSG Partners Foundation Workshop
Recognition and management of organ-specific toxicities associated with enfortumab vedotin plus pembrolizumab and erdafitinib in locally advanced or metastatic urothelial carcinoma
Deep and ultra-deep PSA responses as prognostic biomarkers in metastatic hormone-sensitive prostate cancer. A systematic review and implications for treatment personalization
Corrigendum to “Overcoming Resistance to CDK4/6 inhibitors in Hormone Receptor positive, HER2 negative breast cancer: Innovative Combinations and Emerging Strategies” [Cancer Treat. Rev. 139 (2025) 102980]
Local and systemic inflammatory and immune pathways in anaplastic thyroid carcinoma: emerging therapeutic targets
State-of-the-art treatment of Oesophagogastric junction adenocarcinoma: a systematic review and meta-analysis of randomized clinical trials
PARP inhibitors in breast cancer: From DNA repair targeting to next-generation precision therapeutics
Survival outcomes following neoadjuvant therapy for resectable cholangiocarcinoma: a systematic review and reconstructed individual patient data meta-analysis
Managing the renal primary in metastatic clear-cell RCC in the IO–TKI era: a systemic-first, response-adapted strategy
From drug response to resistance evolution: Leveraging 3D cancer models for functional precision oncology
Bispecific antibodies in lung cancer: From molecular engineering to clinical breakthroughs and translational challenges
MTAP loss in non–small-cell lung Cancer and beyond: Therapeutic targeting of the MAT2A–PRMT5 axis
p53 Co-mutations in EGFR-mutant NSCLC: biological insight and therapeutic implications
Selective estrogen receptor degraders in premenopausal breast cancer: Biological activity and endpoint relevance in window of opportunity trials
Reduced oxaliplatin exposure in gastrointestinal cancers: A systematic review and meta-analysis
Optimizing the treatment pathway in post-docetaxel mCRPC: PSMA-RLT vs cabazitaxel
Advancing therapies for HER2-positive metastatic breast cancer: Navigating a wealth of treatment options
“Current approaches and emerging strategies in the treatment of ductal carcinoma in situ and premalignant breast lesions”
Molecular tumor boards implementation in Europe: a scoping review and thematic analysis of challenges and facilitators
Immune checkpoint inhibitor resistance in gastric and colorectal cancers
Co-targeting VEGF and PD-(L)1 in gastrointestinal cancers: biology, clinical landscape, and therapeutic frontiers
Tissue and blood-based biomarkers of immunotherapy response in head and neck Cancer
Editorial Board
Fusobacterium nucleatum and response to treatment in colon and rectal cancer: a systematic review
Comparative analysis of patient-derived organoids and patient-derived xenografts as avatar models for predicting response to anti-cancer therapy
Immunotherapy for locally advanced head and neck squamous cell carcinoma: A review
Expanding the path to cure - a narrative review on optimizing multimodality sequencing in HCC
Adjuvant chemotherapy in stage I triple-negative breast cancer: A systematic review and meta-analysis of survival outcomes
Clinical efficacy and immunological aspects of neoadjuvant and perioperative therapy in resectable head and neck carcinoma
The antibiotic-immunotherapy interaction in NSCLC: a systematic review and meta-analysis of 54,250 patients across three outcomes
Volumes
2026 · 1292025 · 1302024 · 1412023 · 992022 · 1092021 · 1182020 · 1182019 · 842018 · 1572017 · 1392016 · 1212015 · 1152014 · 1402013 · 1142012 · 1172011 · 782010 · 1922009 · 962008 · 2072007 · 902006 · 942005 · 1032004 · 1062003 · 1062002 · 442001 · 522000 · 441999 · 541998 · 441997 · 351996 · 571995 · 391994 · 281993 · 541991 · 321990 · 761989 · 461988 · 391987 · 521986 · 17
EUVIMED